{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:31:11Z","timestamp":1761093071430,"version":"build-2065373602"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cytogenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Myeloid\/Lymphoid Neoplasms (MLN) with eosinophilia and <jats:italic>PDGFRB<\/jats:italic> rearrangements are rare but distinct hematologic malignancies driven by the constitutive activation of the <jats:italic>PDGFRB<\/jats:italic> tyrosine kinase through gene fusions. These neoplasms are sensitive to tyrosine kinase inhibitors (TKIs) such as imatinib, which often leads to rapid and durable molecular remissions. However, diagnostic challenges frequently arise from cryptic rearrangements, necessitating comprehensive molecular approaches.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 37-year-old male patient initially presented with pancytopenia and a splenic infarct; subsequent bone marrow findings were suggestive of a myeloid\/lymphoid neoplasm. Initial conventional cytogenetic analysis and fluorescence in situ hybridization (FISH) identified a <jats:italic>PDGFRB<\/jats:italic> gene rearrangement but were unable to fully resolve the structural complexity of the underlying genomic alteration. Long-read sequencing helped resolve a complex three-way translocation involving chromosomes 5, 12, and 20, precisely defining the <jats:italic>ETV6::PDGFRB<\/jats:italic> fusion with base pair resolution, and identified the partner gene (<jats:italic>KAT14<\/jats:italic>) on chromosome 20p. Following the diagnosis, the patient was started on imatinib therapy and has since achieved clinical and hematological improvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This case highlights the significant diagnostic utility of long-read sequencing in uncovering and characterizing cryptic and complex genomic rearrangements that are frequently missed by conventional methods. Accurate molecular characterization is critical for disease classification, guiding targeted therapeutic decisions, and ultimately improving patient outcomes in <jats:italic>PDGFRB<\/jats:italic>-rearranged neoplasms.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13039-025-00730-7","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:03:01Z","timestamp":1761040981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-read sequencing unmasks a cryptic three-way translocation resulting in an ETV6::PDGFRB fusion"],"prefix":"10.1186","volume":"18","author":[{"given":"Joseph","family":"Tripodi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiva","family":"Ahire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"Najfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"11","key":"730_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. The international consensus classification of myeloid neoplasms and acute leukemias: integrating morphological, clinical, and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"issue":"2","key":"730_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00277-021-04712-8","volume":"101","author":"DD Giacomo","year":"2022","unstructured":"Giacomo DD, Quintini M, Pierini V, Pellanera F, Starza RL, Gorello P, et al. Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement. Ann Hematol. 2022;101(2):297\u2013307.","journal-title":"Ann Hematol"},{"issue":"2","key":"730_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ajcp\/aqaa208","volume":"155","author":"O Pozdnyakova","year":"2020","unstructured":"Pozdnyakova O, Orazi A, Kelemen K, King R, Reichard KK, Craig FE, et al. Myeloid\/Lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2. Am J Clin Pathol. 2020;155(2):160\u201378.","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"730_CR4","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/his.14097","volume":"76","author":"H Fang","year":"2020","unstructured":"Fang H, Tang G, Loghavi S, Greipp P, Wang W, Verstovsek S, et al. Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid\/lymphoid neoplasms. Histopathology. 2020;76(7):1042\u201354.","journal-title":"Histopathology"},{"issue":"1","key":"730_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/emboj\/16.1.69","volume":"16","author":"C Jousset","year":"1997","unstructured":"Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL\u2013PDGFR\u03b2 oncoprotein. EMBO J. 1997;16(1):69\u201382.","journal-title":"EMBO J"},{"issue":"1","key":"730_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","volume":"109","author":"M David","year":"2007","unstructured":"David M, Cross NCP, Burgstaller S, Chase A, Curtis C, Dang R, et al. Durable responses to imatinib in patients with PDGFRB fusion gene\u2013positive and BCR-ABL\u2013negative chronic myeloproliferative disorders. Blood. 2007;109(1):61\u20134.","journal-title":"Blood"},{"issue":"1","key":"730_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","volume":"23","author":"Q Gao","year":"2018","unstructured":"Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 2018;23(1):227-238.e3.","journal-title":"Cell Rep"},{"key":"730_CR8","first-page":"9","volume":"1","author":"J Geyer","year":"2025","unstructured":"Geyer J, Opoku KB, Lin J, Ramkissoon L, Mullighan C, Bhakta N, et al. Real-time genomic characterization of pediatric acute leukemia using adaptive sampling. Leukemia. 2025;1:9.","journal-title":"Leukemia"},{"issue":"2","key":"730_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3324\/haematol.10980","volume":"92","author":"C Walz","year":"2007","unstructured":"Walz C, Metzgeroth G, Haferlach C, Schmitt-Graeff A, Fabarius A, Hagen V, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor \u03b2 gene. Haematologica. 2007;92(2):163\u20139.","journal-title":"Haematologica"},{"issue":"0","key":"730_CR10","doi-asserted-by":"publisher","first-page":"8841","DOI":"10.2147\/CMAR.S324718","volume":"13","author":"A Borogovac","year":"2021","unstructured":"Borogovac A, Sahu KK, Vishwanathan GK, Miron PM, Cerny J. A case of acute myeloid leukemia harboring a rare three-way translocation t(5;7;7) involving the PDGFRB gene and successfully treated with imatinib. Cancer Manag Res. 2021;13(0):8841\u20137.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"730_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cancergencyto.2007.03.004","volume":"176","author":"B Crescenzi","year":"2007","unstructured":"Crescenzi B, Starza RL, Nozzoli C, Ciolli S, Matteucci C, Romoli S, et al. Molecular cytogenetic findings in a four-way t(1;12;5;12)(p36;p13;q33;q24) underlying the ETV6-PDGFRB fusion gene in chronic myelomonocytic leukemia. Cancer Genet Cytogenet. 2007;176(1):67\u201371.","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"730_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/leu.2016.250","volume":"31","author":"K Byrgazov","year":"2017","unstructured":"Byrgazov K, Kastner R, Gorna M, Hoermann G, Koenig M, Lucini CB, et al. NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors. Leukemia. 2017;31(1):237\u201340.","journal-title":"Leukemia"},{"issue":"20","key":"730_CR13","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1182\/blood-2017-11-817510","volume":"131","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Gao Y, Zhang H, Zhang J, He F, Hn\u00edzda A, et al. PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood. 2018;131(20):2256\u201361.","journal-title":"Blood"},{"issue":"5","key":"730_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1182\/bloodadvances.2024013800","volume":"9","author":"M Zhao","year":"2025","unstructured":"Zhao M, Ryall S, Brody SJ, Harris AC, Cabral K, Brownstein C, et al. Integrative cytogenetic and molecular studies unmask \u201cchromosomal mimicry\u201d in hematologic malignancies. Blood Adv. 2025;9(5):1003\u201312.","journal-title":"Blood Adv"}],"container-title":["Molecular Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13039-025-00730-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13039-025-00730-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13039-025-00730-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:03:03Z","timestamp":1761040983000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularcytogenetics.biomedcentral.com\/articles\/10.1186\/s13039-025-00730-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1186\/s13039-025-00730-7","relation":{},"ISSN":["1755-8166"],"issn-type":[{"value":"1755-8166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Mount Sinai Institutional Review Board (IRB study number: 24\u201300240) and was in accordance with the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was not obtained as this was a retrospective study utilizing de-identified data. No identifiable images from human research participants were used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}